One fact currently puzzling ALS researchers and clinicians is the diverse survival times ranging from less than a year to over 10 years. Such a wide range makes it difficult to predict disease progression and survival, and suggests rather large underlying disease heterogeneity. There may exist different subgroups of patients (i.e., \pc), each